



Company Contact:
Richard Gabriel
CEO and President
941 366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

FOR IMMEDIATE RELEASE:

**DNAPRINT GENOMICS STUDY CONCLUDES TESTING COULD AID IN
TREATMENTS FOR NAUSEA AND VOMITING**

Company Sees Large Potential Market

SARASOTA, Fla., Sept. 27, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the results of a recently-completed market research study by the Diagnostics division of the Company’s Pharmaceuticals subsidiary which showed a large potential market for DNA tests that would better predict which patients are prone to Post Operative Nausea and Vomiting (PONV).

PONV occurs in up to 50% of post-operative patients. Today, most patients receive one or several drugs to relieve PONV, but these drugs—called antiemetics—are only effective in approximately 50% of the patients. There are several known risk factors for PONV. The observations that there seems to be individual susceptibility to PONV, and that many individuals have a family history of PONV, led investigators to explore the possibility that there are in-born, genetic predisposing factors that may contribute to PONV. DNAPrint and collaborators at the Moffitt Cancer Center in Tampa, Fla., conducted a pilot study, which was reported at an international anesthesia research conference last March. Initial results were promising enough to trigger the Company to sponsor market research conducted by Blomquist Associates of Boulder, Colo.

Anesthesiologists included in the survey appreciate the value of a properly administered DNA test that would identify which patients with PONV would respond to which of several antiemetic drugs, which in turn would help doctors to administer the proper treatment. The net result of fewer patients experiencing PONV, and those that do experience it receiving more effective treatment, could translate into significantly reduced hospital costs as patients spend less time in recovery rooms. Additionally, fewer patients would receive unnecessary, expensive drugs .

“Based on very consistent messages we obtained in our survey, we have advanced our pilot program in discovery of genetic predictors of PONV from pure research to development.” Said Hector J. Gomez, Chief Medical Officer and Chairman of the Board. “We are taking a market driven approach in selecting our new programs in predictive test development in the Diagnostics division, so that we have a clear commercialization path for each test.”

Although PONV is rarely life threatening, patients ranked it at the top of their concerns about surgery. Anesthesiologists interviewed indicated that their colleagues are aware of this concern and recognize that while patient factors such as gender and previous history are helpful in predicting PONV, gene tests, if proven, could greatly improve patient care.

(MORE)

“We are very enthusiastic about the potential to design clinico-genetic risk models of adverse outcomes of surgery, including especially PONV, because the operating team will be able to use that information to promote healthier outcomes for their patients immediately,” stated Barbara Handelin, Ph.D., Director of Diagnostics at DNA Print Pharmaceuticals. “Our assessment of the interest of anesthesiologists in such a risk model including tests we are developing indicate that the market is very ready and sizeable.”

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###